Laila Gharzai, MD, discusses findings from the BRIGHTSTAR trial which evaluated brigatinib in TKI-naïve patients with ALK-rearranged metastatic non–small cell lung cancer.
Immunotherapy/Radiation Shows Responses in NSCLC Brain Metastases
Retrospective data may offer actionable guidance for clinicians treating patients with non–small cell lung cancer and brain metastases.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
3 Things You Should Know About Managing ALK+ Metastatic NSCLC
Multidisciplinary approaches, RNA-based next-generation sequencing, and patient-specific front-line treatment decisions are all important for curating effective NSCLC treatments.
Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology
Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.
Ivonescimab Prolonged PFS vs Pembrolizumab in PD-L1+, Treatment-Naïve NSCLC
Ivonescimab demonstrated a broad prolongation of PFS across various prespecified subgroups in patients with treatment-naïve, PD-L1–positive NSCLC.
Rezivertinib Improves PFS vs Gefitinib in EGFR-Mutant NSCLC
Results from the phase 3 REZOR trial show a median PFS of 19.3 months with rezivertinib vs 9.6 months with gefitinib in patients with NSCLC.